References

Banati, R.B., S.E. Daniel and S.B. Blunt, 1998. Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinsons disease. Mov. Disord. Off. J. Mov. Disord. Soc., 13: 221-227.
CrossRef  |  PubMed  |  Direct Link  |  

Bonifati, V., P. Rizzu, M.J. Van Baren, O. Schaap and G.J. Breedveld et al., 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Sci., 299: 256-259.
CrossRef  |  Direct Link  |  

Burli, R.W., C.A. Luckhurst, O. Aziz, K.L. Matthews and D. Yates et al., 2013. Design, synthesis and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntingtons disease. J. Med. Chem., 56: 9934-9954.
CrossRef  |  PubMed  |  Direct Link  |  

Camelo, S., A.H. Iglesias, D. Hwang, B. Due and H. Ryu et al., 2005. Transcriptional therapy with the histone deacetylase inhibitor trichostatin a ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol., 164: 10-21.
CrossRef  |  PubMed  |  Direct Link  |  

Carey, N. and N.B. La Thangue, 2006. Histone deacetylase inhibitors: Gathering pace. Curr. Opin. Pharmacol., 6: 369-375.
CrossRef  |  Direct Link  |  

Chopra, V., L. Quinti, J. Kim, L. Vollor and K.L. Narayanan et al., 2012. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntingtons disease mouse models. Cell Rep., 2: 1492-1497.
CrossRef  |  PubMed  |  Direct Link  |  

Chuang, D.M., Y. Leng, Z. Marinova, H.J. Kim and C.T. Chiu, 2009. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci., 32: 591-601.
CrossRef  |  PubMed  |  Direct Link  |  

Cook, C., Y. Carlomagno, T.F. Gendron, J. Dunmore and K. Scheffel et al., 2013. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet., 23: 104-116.
CrossRef  |  PubMed  |  Direct Link  |  

Coppede, F., 2012. Genetics and epigenetics of Parkinsons disease. Sci. World J., 2012: 1-12.
CrossRef  |  Direct Link  |  

Coppede, F., 2013. Advances in the genetics and epigenetics of neurodegenerative diseases. Epigenet. Degenerative Dis., 1: 3-31.
Direct Link  |  

Coppede, F., 2014. The potential of epigenetic therapies in neurodegenerative diseases. Front. Genet., 5: 1-8.
CrossRef  |  PubMed  |  Direct Link  |  

Coppieters, N., B.V. Dieriks, C. Lill, R.L. Faull and M.A. Curtis et al., 2014. Global changes in DNA methylation and hydroxymethylation in Alzheimers disease human brain. Neurobiol. Aging, 35: 1334-1344.
CrossRef  |  Direct Link  |  

Cudkowicz, M.E., P.L. Andres, S.A. Macdonald, R.S. Bedlack and R. Choudry et al., 2009. Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis, 10: 99-106.
CrossRef  |  

Dal Piaz, F., A. Tosco, D. Eletto, A.L. Piccinelli and O. Moltedo et al., 2010. The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. Chem. Biochem., 11: 818-827.
CrossRef  |  PubMed  |  Direct Link  |  

Dasgupta, S., Y. Zhou, M. Jana, N.L. Banik and K. Pahan, 2003. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J. Immunol., 170: 3874-3882.
CrossRef  |  PubMed  |  Direct Link  |  

Del Signore, S.J., D.J. Amante, J. Kim, E.C. Stack and S. Goodrich et al., 2009. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotrophic Lateral Sclerosis, 10: 85-98.
CrossRef  |  

Desplats, P., B. Spencer, E. Coffee, P. Patel and S. Michael et al., 2011. A-synuclein sequesters dnmt1 from the nucleus a novel mechanism for epigenetic alterations in lewy body diseases. J. Biol. Chem., 286: 9031-9037.
PubMed  |  Direct Link  |  

Ding, H., P.J. Dolan and G.V. Johnson, 2008. Histone deacetylase 6 interacts with the microtubule‐associated protein Tau. J. Neurochem., 106: 2119-2130.
CrossRef  |  Direct Link  |  

Duan, W., 2013. Targeting sirtuin-1 in Huntingtons disease: Rationale and current status. CNS. Drugs, 27: 345-352.
CrossRef  |  PubMed  |  Direct Link  |  

Feng, H.L., Y. Leng, C.H. Ma, J. Zhang and M. Ren et al., 2008. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neurosci., 155: 567-572.
CrossRef  |  PubMed  |  Direct Link  |  

Fischer, A., F. Sananbenesi, X. Wang, M. Dobbin and L.H. Tsai, 2007. Recovery of learning and memory is associated with chromatin remodelling. Nature, 447: 178-182.
CrossRef  |  Direct Link  |  

Goers, J., A.B. Manning-Bog, A.L. McCormack, I.S. Millett and S. Doniach et al., 2003. Nuclear localization of α-synuclein and its interaction with histones. Biochem., 42: 8465-8471.
CrossRef  |  PubMed  |  Direct Link  |  

Graff, J., D. Rei, J.S. Guan, W.Y. Wang and J. Seo et al., 2012. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nat., 483: 222-226.
PubMed  |  Direct Link  |  

Gray, S.G. and F. Dangond, 2006. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenet., 1: 67-75.
CrossRef  |  PubMed  |  Direct Link  |  

Gray, S.G., 2010. Targeting histone deacetylases for the treatment of Huntingtons disease. CNS. Neurosci. Ther., 16: 348-361.
CrossRef  |  Direct Link  |  

Harrison, I.F. and D.T. Dexter, 2013. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinsons disease?. Pharmacol. Ther., 140: 34-52.
CrossRef  |  Direct Link  |  

Jakovcevski, M. and S. Akbarian, 2012. Epigenetic mechanisms in neurological disease. Nat. Med., 18: 1194-1204.
PubMed  |  Direct Link  |  

Janssen, C., S. Schmalbach, S. Boeselt, A. Sarlette and R. Dengler et al., 2010. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol., 69: 573-581.
CrossRef  |  Direct Link  |  

Jenuwein, T. and C.D. Allis, 2001. Translating the histone code. Science, 293: 1074-1080.
CrossRef  |  Direct Link  |  

Jia, H., R.J. Kast, J.S. Steffan and E.A. Thomas, 2012. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntingtons disease mice: Implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet., 21: 5280-5293.
PubMed  |  Direct Link  |  

Jiang, H., M.A. Poirier, Y. Liang, Z. Pei and C.E. Weiskittel et al., 2006. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis., 23: 543-551.
CrossRef  |  PubMed  |  Direct Link  |  

Karagiannis, T.C. and K. Ververis, 2012. Potential of chromatin modifying compounds for the treatment of Alzheimers disease. Pathobiology Aging Age Relat. Dis., 2: 1-8.
CrossRef  |  Direct Link  |  

Kilgore, M., C.A. Miller, D.M. Fass, K.M. Hennig and S.J. Haggarty et al., 2010. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology, 35: 870-880.
CrossRef  |  PubMed  |  Direct Link  |  

Kontopoulos, E., J.D. Parvin and M.B. Feany, 2006. A-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet., 15: 3012-3023.
CrossRef  |  PubMed  |  Direct Link  |  

Kouzarides, T., 2007. Chromatin modifications and their function. Cell, 128: 693-705.
CrossRef  |  PubMed  |  Direct Link  |  

Langley, B., M.A. D’Annibale, K. Suh, I. Ayoub and A. Tolhurst et al., 2008.. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21^waf1/cip1 in cell cycle-independent neuroprotection. J. Neurosci., 28: 163-176.
CrossRef  |  PubMed  |  Direct Link  |  

Laurent, R.S., L.M. O’Brien and S.T. Ahmad, 2013. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinsons disease. Neurosci., 246: 382-390.
PubMed  |  Direct Link  |  

Leng, Y. and D.M. Chuang, 2006. Endogenous a-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci., 26: 7502-7512.
CrossRef  |  PubMed  |  Direct Link  |  

Levenson, J.M. and J.D. Sweatt, 2005. Epigenetic mechanisms in memory formation. Nat. Rev. Neurosci., 6: 108-118.
Direct Link  |  

Ling, Z., L. Cui, W. Jie, T. Jing-jing and S. Xiao-long et al., 2014. Tubastatin A/ACY-1215 improves cognition in Alzheimers disease transgenic mice. J. Alzheimers Dis., 41: 1193-1205.
CrossRef  |  PubMed  |  Direct Link  |  

Mehler, M.F., 2008. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Prog. Neurobiol., 86: 305-341.
CrossRef  |  PubMed  |  Direct Link  |  

Migliore, L. and F. Coppede, 2009. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res., 667: 82-97.
CrossRef  |  

Minucci, S. and P.G. Pelicci, 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 6: 38-51.
Direct Link  |  

Moller, T., 2010. Neuroinflammation in Huntingtons disease. J. Neural Trans., 117: 1001-1008.
CrossRef  |  Direct Link  |  

Monti, B., V. Gatta, F. Piretti, S.S. Raffaelli and M. Virgili et al., 2010. Valproic acid is neuroprotective in the rotenone rat model of Parkinsons disease: Involvement of a-synuclein. Neurotoxic. Res., 17: 130-141.
CrossRef  |  PubMed  |  Direct Link  |  

Nambirajan, G., A.B.R. Carlos, W. Jonas, S. Farahnaz and F. Andre, 2011. Sodium butyrate improves memory function in an Alzheimers disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis., 26: 187-197.
CrossRef  |  PubMed  |  Direct Link  |  

Outeiro, T.F., E. Kontopoulos, S.M. Altmann, I. Kufareva and K.E. Strathearn et al., 2007. Sirtuin 2 inhibitors rescue a-synuclein-mediated toxicity in models of Parkinsons disease. Sci., 317: 516-519.
CrossRef  |  PubMed  |  Direct Link  |  

Piepers, S., J.H. Veldink, S.W. De Jong, I. Van Der Tweel and W.L. Van Der Pol et al., 2009. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc., 66: 227-234.
CrossRef  |  PubMed  |  Direct Link  |  

Pirooznia, S.K., J. Sarthi, A.A. Johnson, M.S. Toth and K. Chiu et al., 2012. Tip60 HAT activity mediates APP induced lethality and apoptotic cell death in the CNS of a Drosophila Alzheimers disease model. PlOS. One, 7: 1-13.
PubMed  |  Direct Link  |  

Rajendran, P., E. Ho, D.E. Williams and R.H. Dashwood, 2011. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin. Epigenetics, Vol. 3.

Rane, P., J. Shields, M. Heffernan, Y. Guo and S. Akbarian et al., 2012. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacol., 62: 2409-2412.
CrossRef  |  PubMed  |  Direct Link  |  

Ricobaraza, A., M. Cuadrado‐Tejedor, S. Marco, I. Perez‐Otano and A. Garcia‐Osta, 2012. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus, 22: 1040-1050.
CrossRef  |  PubMed  |  Direct Link  |  

Rodenhiser, D. and M. Mann, 2006. Epigenetics and human disease: Translating basic biology into clinical applications. Can. Med. Assoc. J., 174: 341-348.
CrossRef  |  PubMed  |  Direct Link  |  

Rouaux, C., N. Jokic, C. Mbebi, S. Boutillier and J.P. Loeffler et al., 2003. Critical loss of CBP/p300 histone acetylase activity by caspase‐6 during neurodegeneration. Eur. Mol. Biol. J., 22: 6537-6549.
CrossRef  |  PubMed  |  Direct Link  |  

Ryu, H., J. Lee, B.A. Olofsson, A. Mwidau and A. Deodoglu et al., 2003. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. National Acad. Sci., 100: 4281-4286.
CrossRef  |  PubMed  |  Direct Link  |  

Ryu, H., J. Lee, S.W. Hagerty, B.Y. Soh and S.E. McAlpin et al., 2006. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntingtons disease. Proc. National Acad. Sci., 103: 19176-19181.
CrossRef  |  PubMed  |  Direct Link  |  

Ryu, H., K. Smith, S.I. Camelo, I. Carreras and J. Lee et al., 2005. Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem., 93: 1087-1098.
CrossRef  |  PubMed  |  Direct Link  |  

Saha, R.N. and K. Pahan, 2006. HATs and HDACs in neurodegeneration: A tale of disconcerted acetylation homeostasis. Cell Death Different., 13: 539-550.
CrossRef  |  PubMed  |  Direct Link  |  

Selenica, M.L., L. Benner, S.B. Housley, B. Manchec and D.C. Lee et al., 2014. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimers Res. Therapy, 6: 1-12.
CrossRef  |  PubMed  |  Direct Link  |  

Song, C., A. Kanthasamy, V. Anantharam, F. Sun and A.G. Kanthasamy, 2010. Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: Relevance to epigenetic mechanisms of neurodegeneration. Mol. Pharmacol., 77: 621-632.
PubMed  |  Direct Link  |  

Steffan, J.S., A. Kazantsev, O. Spasic-Boskovic, M. Greenwald and Y.Z. Zhu et al., 2000. The Huntington's disease protein interacts with p53 and CREB binding protein and represses transcription. Proc. Nat. Acad. Sci., 97: 6763-6768.
CrossRef  |  

Steffan, J.S., L. Bodai, J. Pallos, M. Poelman and A. McCampbell et al., 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nat., 413: 739-739.
PubMed  |  Direct Link  |  

Sugai, F., Y. Yamamoto, K. Miyaguchi, Z. Zhou and H. Sumi et al., 2004. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci., 20: 3179-3183.
PubMed  |  Direct Link  |  

Sung, Y.M., T. Lee, H. Yoon, A.M. DiBattista and J.M. Song et al., 2013. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp. Neurol., 239: 192-201.
CrossRef  |  

Tsankova, N., W. Renthal, A. Kumar and E.J. Nestle, 2007. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci., 8: 355-367.
CrossRef  |  

Vincenzo, P., A. Anella, W. D'Acunto, C. Festa and C. Anna, 2011. Neuroinflamm-aging and neurodegenerative diseases: An overview. CNS. Neurol. Disord. Drug Targets, 10: 621-634.
CrossRef  |  Direct Link  |  

Wang, Y., X. Wang, L. Liu and X. Wang, 2009. HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci. Lett., 467: 212-216.
CrossRef  |  PubMed  |  Direct Link  |  

Wood, M.A., J.D. Hawk and T. Abel, 2006. Combinatorial chromatin modifications and memory storage: A code for memory?. Learn. Memory, 13: 241-244.
CrossRef  |  PubMed  |  Direct Link  |  

Yitshak, F., F. Mauroa, A. Haidera, Z. Honga and S. Agnieszkaa et al., 2009. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimers disease. J. Alzheimers Dis., 18: 131-139.
CrossRef  |  PubMed  |  Direct Link  |  

Yoo, Y.E. and C.P. Ko, 2011. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 231: 147-159.
PubMed  |  Direct Link  |  

Zhang, K., M. Schrag, A. Crofton, R. Trivedi and H. Vinters et al., 2012. Targeted proteomics for quantification of histone acetylation in lzheimers disease. Proteomics, 12: 1261-1268.
CrossRef  |  PubMed  |  Direct Link  |  

Zhang, Z.Y. and H.J. Schluesener, 2013. Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J. Neuropathol. Exp. Neurol., 72: 178-185.
CrossRef  |  PubMed  |  Direct Link  |  

Zhou, W., K. Bercury, J. Cummiskey, N. Luong and J. Lebin et al., 2011. Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J. Biol. Chem., 286: 14941-14951.
CrossRef  |  PubMed  |  Direct Link  |  

Zhu, M., W.W. Li and C.Z. Lu, 2014. Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS. Neurosci. Ther., 20: 308-316.
CrossRef  |  PubMed  |  Direct Link  |